Stock MEDINCELL
Add to a list
To use this feature you must be a member
Log inSign up

MedinCell Share Price LIQUIDNET SYSTEMS

Equities

FR0004065605

Pharmaceuticals

End-of-day quote LIQUIDNET SYSTEMS
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for MedinCell -.--% -.--%
06-10 Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
06-10 Medincell: a 'new era' after a 'pivotal' 2023 CF
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 13.96M 15.03M 1.18B Sales 2025 * 41.8M 45.02M 3.54B Capitalization 432M 466M 36.58B
Net income 2024 * -23M -24.77M -1.95B Net income 2025 * -1M -1.08M -84.6M EV / Sales 2024 * 34.3 x
Net Debt 2024 * 46.97M 50.58M 3.97B Net Debt 2025 * 57.43M 61.85M 4.86B EV / Sales 2025 * 11.7 x
P/E ratio 2024 *
-16.3 x
P/E ratio 2025 *
-58.4 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.05%
More Fundamentals * Assessed data

Chart MedinCell

Dynamic Chart

Latest news about MedinCell

Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
Medincell: a 'new era' after a 'pivotal' 2023 CF
Medincell: share price falls after disappointing clinical study CF
Transcript : MedinCell S.A. - Special Call
Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial CI
Medincell: share price rises on resumption of trading CF
CAC40: remains in green in a neglected market CF
Medincell: positive results in schizophrenia CF
Medincell Listing Temporarily Suspended on Euronext Paris MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study RE
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia CI
CAC40: in green, builds on previous day's momentum CF
Medincell: listing suspended pending a press release CF
Medincell: share price rises following agreement with AbbVie CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics DJ
More news

Latest transcript on MedinCell

Logo MedinCell
MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
More transcripts

Analyst Recommendations on MedinCell

MedinCell: share price continues to rise, Jefferies to buy CF
MedinCell: share price surges, broker in support CF
MEDINCELL : Oddo raises its target price on the stock CF
More recommendations

Press releases MedinCell

Medincell Publishes Its Consolidated Annual Financial Results BU
Medincell: Publication of the Financial Results for the 2023-2024 Fiscal Year and Videoconference on Monday, June 10, 2024 BU
Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate) BU
Medincell: Update of the 2024 Financial Calendar BU
Medincell to Present at the 2024 Jefferies Global Healthcare Conference, June 4 to 6, 2024, New York BU
More press releases

News in other languages on MedinCell

Medincell : une 'nouvelle ère' après une année 2023 'pivot'
MedinCell S A : a réduit sa perte en 2023
Le jour de la marmotte
En Direct des Marchés : Stellantis, Crédit Agricole, LVMH, Volvo, Microsoft, Apple, Southwest Airlines...
Medincell publie ses résultats financiers annuels consolidés
More news

Managers and Directors - MedinCell

Managers TitleAgeSince
Christophe Douat CEO
 Chief Executive Officer 60 08/01/03
Stéphane Postic DFI
 Director of Finance/CFO 50 31/08/23
Adolfo Lopez-Noriega CTO
 Chief Tech/Sci/R&D Officer - 31/12/14
Members of the board TitleAgeSince
Sabri Markabi BRD
 Director/Board Member - 04/07/17
Tone Kvåle BRD
 Director/Board Member 55 12/06/22
Virginie Lleu BRD
 Director/Board Member - 24/05/16
More insiders

Company Profile

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
25/06/2024 - Q4 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for MedinCell

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.88 EUR
Average target price
18.44 EUR
Spread / Average Target
+23.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.39% 779B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.13% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.61% 333B
ABBVIE INC. Stock AbbVie Inc.
+10.00% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.87% 249B
ROCHE HOLDING AG Stock Roche Holding AG
-1.96% 216B
NOVARTIS AG Stock Novartis AG
+11.11% 214B
AMGEN INC. Stock Amgen Inc.
+5.80% 163B
PFIZER, INC. Stock Pfizer, Inc.
-2.50% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW